More recently, a retrospective study (CCTG CO.20) performed in 595 patients with metastatic wild-type KRAS CRC treated with cetuximab found an improved OS in the FcγRIIa-131H/H genotype group (n=165) compared to those with R/‐ genotype (n=427) (HR=0.66; p<0.001; median absolute benefit, 1.3 months) (28). The gene discussed is KRAS; the disease is colorectal carcinoma.